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Although hepatic dysfunction is common in adult-onset Still’s disease (AOSD), sometimes it is diﬃcult to diﬀerentiate hepatic
dysfunction due to AOSD itself from drug-induced hepatic dysfunction. Further, myalgia often occurs in patients with AOSD;
however, AOSD patients complicated with myositis are rare. We report a 43-year-old Japanese man with AOSD who developed
myositis and hepatic dysfunction which were deteriorated by multiple nonsteroidal antiinﬂammatory drugs (NSAIDs) and were
dramaticallyamelioratedbyalow-dosesteroidtherapy.AskinbiopsyofsalmonpinkrashwhichischaracteristicforAOSDshowed
leukocytoclastic vasculitis, and the markers for vasculitis, plasma von Willebrand factor, and vascular endothelial growth factor
levels were elevated in this patient, suggesting an association between AOSD and systemic vasculitis.
Copyright © 2009 Hidekatsu Yanai et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Adult-onset Still’s disease (AOSD) is a rare systemic inﬂam-
matory disease of unknown etiology. Hepatic dysfunction is
common in AOSD, and more than 70% of these patients
show elevated liver enzymes [1]. Evanescent salmon-pink
rash is characteristic for AOSD; however, the histopathology
of this rash has not been cleared. Although myalgia often
occurs in AOSD, myositis complicated with AOSD is rare
[2]. Here, we describe a patient with AOSD who developed
myositis and hepatic dysfunction which were deteriorated
by multiple nonsteroidal anti-inﬂammatory drugs (NSAIDs)
and were dramatically ameliorated by a low-dose steroid
therapy. Further, we also show the association between
AOSD and vasculitis by presenting the pathologic ﬁndings
of salmon-pink rash and elevated markers for vasculitis in
AOSD.
2. Case Presentation
A 43-year old Japanese man was referred and admitted with
a continuous spiking fever, myalgia, and arthralgia. Physical
examination revealed fever, muscle weakness, and salmon-
pink rash (Figure 1). Laboratory examination was notable
for a C-reactive protein (CRP) level of 1.1mg/dL (normal
range, 0.0–0.3), a ﬁbrinogen level of 504mg/dL (normal
range, 150–400), a creatin kinase (CK) level of 1.114IU/L
(normal range, 55–200), and a ferritin level of 2.892ng/mL
(normal range, 40–350). Serum rheumatoid factor, antin-
uclear antigen, proteinase 3 (PR3)- and myeloperoxidase
(MPO)-antineutrophilcytoplasmicautoantibodies(ANCA),
and anti-Jo-1 antibody were negative. He was diagnosed as
AOSD based on Yamaguchi’s criteria [3].
Needle electromyography showed active myogenic
change in right biceps femoris muscle and deltoid muscle.
A skin biopsy of salmon pink rash showed perivascular
lymphocytes inﬁltration and fragmentation of blood cells,
which was compatible with leukocytoclastic vasculitis
(Figure 2). Markers for vasculitis, plasma von Willebrand
factor (vWF) (235% (normal range, 60–170)), and vascular
endothelial growth factor (VEGF) (1.050pg per milliliter
(normal range <115)) were elevated.
Acetaminophne, loxoprofen sodium, and meloxicam
decreased his fever, serum CRP, and ferritin levels; however,
these NSAIDs elevated serum aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and CK levels2 Case Reports in Medicine
Figure 1: Salmon-pink rash on the patient’s upper arm.
(Figure 3). A 20mg corticosteroid therapy promptly amelio-
ratedpatient’ssymptomsanddecreasedserumAST,ALT,and
CK (Figure 3).
3. Discussion
To our knowledge, the histopathology of evanescent salmon-
pink rash has not been cleared. A skin biopsy revealed
that rash was due to leukocytoclastic vasculitis. Leukocyto-
clastic vasculitis is characterized by angiocentric segmental
inﬂammation, ﬁbrinoid necrosis, and a neutrophilic inﬁl-
trate around the vessel walls with erythrocyte extravasa-
tion [4]. Leukocytoclastic vasculitis has been observed in
Henoch-Sch¨ onlein purpura, Wegener’s granulomatosis, and
microscopic polyangiitis [5–7]; however, it has not been
reported in AOSD. Negative PR3- and MPO-ANCA denied
complication with Wegener’s granulomatosis or microscopic
polyangiitis in our patient.
vWF is produced by blood vessel endothelial cells in
response to injury, and high vWF level has been observed in
systemic vasculitis [8]. VEGF is a cytokine participating in
inﬂammation with potent endothelial eﬀect and is produced
by macrophages, neutrophils, and vascular endothelial cells
and can alter vascular permeability. VEGF has also been
suggested to be associated with vasculitis, and elevated
s e r u mV E G Fl e v e l sh a v eb e e no b s e r v e di nB e h c ¸et’s disease,
microscopic polyangiitis, polyarteritis nodosa, and giant cell
arteritis [9–12]. Elevated blood vWF and VEGF levels in
our AOSD patient suggest a signiﬁcant association between
AOSD and vasculitis. We have to mention that VEGF
immunostaining on the cutaneous lesion would be more
relevant than serum VEGF measurement, and that we did
not study serum vWF and VEGF levels after the therapy;
however, investigation of changes in their levels after the
(a)
(b)
Figure 2: Histopathological ﬁndings from a salmon-pink rash
showed perivascular lymphocytes inﬁltration and fragmentation of
blood cells, which was compatible with leukocytoclastic vasculitis.
(Hematoxylin-eosin stain; original magniﬁcation: ×25 (a) and ×50
(b).)
corticosteroid therapy would be helpful to show their role in
the pathogenesis of vasculitis in this patient.
Liver dysfunction in AOSD has been ever described in
some case reports. Andr` es et al. retrospectively reviewed data
of 17 patients with AOSD and found abnormalities in liver
biochemistry in 76% of subjects with AOSD, suggesting the
high frequency of liver dysfunction in AOSD [1]. However,
it is diﬃcult to diﬀerentiate liver dysfunction due to AOSD
itself from drug-induced liver dysfunction. Recently, Chen
et al. determined soluble intercellular adhesion molecule 1
(sICAM-1)inpatientswithactiveuntreatedAOSDandiden-
tiﬁedserumsICAM-1levelasapredictorofliverdysfunction
in AOSD, and serum sICAM-1 levels were signiﬁcantly cor-
related with disease activity and serum ferritin levels which
have been also reported to be suitable for monitoring AOSD
disease activity [13]. In our subject, in spite of decrease in
serum CRP and ferritin levels, serum AST and ALT levels
were increased by NSAIDs and were promptly decreased
by corticosteroid, suggesting the presence of drug-induced
liver dysfunction. In this case, NSAIDs also elevated serum
CK levels, and a 20mg corticosteroid therapy promptly
decreased serum CK levels, suggesting NSAIDs-induced
myositis. To our knowledge, drug-induced myositis in AOSD
has not been previously reported. Schwarz-Eywill et al. have
also observed that aspirin improved symptoms and CRPCase Reports in Medicine 3
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Figure 3: Changes in serum C-reactive protein (CRP), ferritin,
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
and creatin kinase (CK) levels in a case with adult-onset Still’s dis-
ease. Therapies A, B, C, and D mean acetaminophen (1500mg/d),
loxoprofen sodium (180mg/d), meloxicam (10mg/d), and corti-
costeroid (20mg/d), respectively.
but increased serum AST and ALT levels in AOSD patients,
and a corticosteroid treatment decreased serum AST and
ALT levels [14]. AOSD may have a potential mechanism
for enhancing drug toxicity. If we ﬁnd deterioration in liver
function and myositis during treatment, in spite of decrease
in CRP and ferritin, we should be aware of drug-induced
hepatitis and myositis in AOSD.
In conclusion, our observation indicates that AOSD may
be associated with systemic vasculitis and also suggests that
we should be aware of the presence of drug-induced hepatitis
and myositis in AOSD.
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